Tirzepatide reduces appetite, energy intake and fat mass in people with type 2 diabetes - Media Centre | EASD
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM
SURPASS-2: A Study Of Tirzepatide Versus Semaglutide Once Weekly As Add-on Therapy To Metformin In Participants With Type 2 Diabetes - My Endo Consult
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial -
First GLP-1/GIP Receptor Agonist OK'd for Type 2 Diabetes | MedPage Today
Why Lilly's tirzepatide has blockbuster potential - Drug Discovery and Development
FDA Approves Tirzepatide, A Potential Blockbuster Drug for Type 2 Diabetes | Biopharma PEG
Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM
The most effective medication for weight loss and blood glucose stabilization: Tirzepatide - On Medicine
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis | SpringerLink
Type 2 Diabetes Treatment to Lower A1C | Mounjaro® (tirzepatide)
Type 2 Diabetes Drug Tirzepatide (Mounjaro) Aids Weight Loss in People With Obesity: Study | Everyday Health
Patients Shed 15% of Body Weight With Tirzepatide, Drugmaker Says | MedPage Today
Vasso's Corner: Tirzepatide, a new era for dual-treatment for type-2 diabetes and obesity - Neos Kosmos
Tirzepatide Slowed Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes with Increased Cardiovascular Risk | ADA
Mounjaro: New Tirzepatide diabetes jab that sparked diabetes row in US could get approved on NHS | The Independent
FDA approves tirzepatide, Eli Lilly's new type 2 diabetes drug, and the company shares an estimated price
Tirzepatide for diabetes: on track to SURPASS current therapy | Nature Medicine
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial | Nature Medicine
December Blog Post: Tirzepatide, Worth the Weight?
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial - The Lancet
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM
